Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Jun 24, 2026 · Filed Jun 29, 2026
The money chief of Cytokinetics sold $3.19M of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$3,187,479
Shares × reported transaction price
50 days after results of May 5, 2026, 43 days before results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.4% | +0.1% | +0.3% |
| 30 days | −5.6% | −0.7% | −4.9% |
| 90 days | −22.3% | +2.5% | −24.9% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$607K of Cytokinetics
Automatic saleDerivative exercise or conversion — not an open-market buy.